Abramson Cancer Center at Penn Medicine: Glioblastoma trials
The registry lists 10 Glioblastoma studies with Abramson Cancer Center at Penn Medicine as lead sponsor. 2 are open to participants now and 0 have results posted.
Early Phase 1 2Phase 1 4Phase 2 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of GlioblastomaRecruitingNCT06613841Early Phase 1
- WBSI Guided Personalized Delivery of TTFieldsRecruitingNCT05086497Not applicable
- Multimodality MRI and Liquid Biopsy in GBMWithdrawnNCT04776980Early Phase 1
- Niraparib/TTFields in GBMActive, not recruitingNCT04221503Phase 2
- Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab TreatmentTerminatedNCT03573986Phase 1
- Personalized Radiation Therapy for GBMCompletedNCT03477513Not applicable
- Evaluating Therapeutic Response to Novo-TTFCompletedNCT02441322Not applicable
- A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV GliomaCompletedNCT01020292Phase 1
- Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma MultiformeTerminatedNCT00915694Phase 1
- Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00128635Phase 1